VOLITIONRX LTD — Director's Dealing 2024

May 24, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VOLITIONRX LTD (VNRX)
CIK: 0000093314
Period of Report: 2024-05-23-05:00

Reporting Person: Retter Andrew (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-05-23-05:00	Common Stock	A	100000	—	Acquired	100000	Direct

Footnotes

F1: In connection with his employment as Chief Medical Officer of Volition Diagnostics UK Limited, Dr. Retter received restricted stock units ("RSUs") subject to a 3-year vesting schedule, vesting as to 33,334 units, 33,333 units, and 33,333 units on each of May 23, 2025, May 23, 2026 and May 23, 2027, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.